Spehner D, Drillien R, Proamer F, Houssais-Pêcheur C, Zanta M A, Geist M, Dott K, Balloul J M
Equipe Propre INSERM 99-08, Transgène, du Sang-Alsace, Strasbourg, France.
Virology. 2000 Jul 20;273(1):9-15. doi: 10.1006/viro.2000.0411.
Modified vaccinia virus Ankara (MVA) is a highly attenuated virus strain that may be useful as a vaccine vector. Ultrastructural examination of purified MVA showed that most of the viral particles are enveloped in contrast to the Copenhagen strain (COP). In CsCl gradients, the majority of the MVA particles displayed a light buoyant density characteristic of the enveloped form. Consistent with these results, MVA particles were poorly labeled with antibodies against the surface of intracellular mature virus but strongly labeled with antibodies against an envelope antigen. Furthermore, MVA was more resistant than the COP strain to neutralization by mouse anti-COP antibodies. These results suggest that the MVA strain may be particularly suitable for the engineering of envelope proteins and that MVA may be able to resist the humoral immunity displayed by previously vaccinated individuals.
安卡拉痘苗病毒(MVA)是一种高度减毒的病毒株,可用作疫苗载体。对纯化的MVA进行超微结构检查发现,与哥本哈根毒株(COP)相比,大多数病毒颗粒都有包膜。在氯化铯梯度中,大多数MVA颗粒呈现出包膜形式的轻浮力密度特征。与这些结果一致,MVA颗粒用抗细胞内成熟病毒表面的抗体标记效果不佳,但用抗包膜抗原的抗体标记效果强烈。此外,MVA比COP毒株对小鼠抗COP抗体的中和作用更具抗性。这些结果表明,MVA毒株可能特别适合用于包膜蛋白的工程改造,并且MVA可能能够抵抗先前接种过疫苗的个体所表现出的体液免疫。